- Stocks
- Healthcare
- NASDAQ: RLAY

Price (delayed)

$19.87

Market cap

$2.16B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.56

Enterprise value

$2.08B

Relay Therapeutics, Inc. operates as a biotechnology company. The Company develops durgs for the treatment of cancer. Relay Therapeutics serves customers in the United States.

The debt has contracted by 7% YoY and by 2% from the previous quarter

The EPS has dropped by 144% year-on-year but it has increased by 35% since the previous quarter

Relay Therapeutics's net income has increased by 30% QoQ but it has decreased by 13% YoY

Relay Therapeutics's revenue has plunged by 98% YoY and by 19% from the previous quarter

RLAY's gross profit has dropped by 98% year-on-year and by 19% since the previous quarter

What are the main financial stats of RLAY

Market
Valuations
Earnings

Shares outstanding

108.9M

Market cap

$2.16B

Enterprise value

$2.08B

Price to earnings (P/E)

N/A

Price to book (P/B)

2.77

Price to sales (P/S)

1,070.28

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

1,029.01

Revenue

$2.02M

EBIT

-$267.12M

EBITDA

-$263.15M

Free cash flow

-$206.44M

Per share
Balance sheet
Liquidity

EPS

-$2.56

Free cash flow per share

-$1.9

Book value per share

$7.18

Revenue per share

$0.02

TBVPS

$8.17

Total assets

$889.42M

Total liabilities

$109.78M

Debt

$22.02M

Equity

$779.64M

Working capital

$811.89M

Debt to equity

0.03

Current ratio

19.49

Quick ratio

19.15

Net debt/EBITDA

0.34

Margins
Efficiency
Dividend

EBITDA margin

-13,046.4%

Gross margin

100%

Net margin

-13,243.6%

Operating margin

-13,426.1%

Return on assets

-30.4%

Return on equity

-34.6%

Return on invested capital

-39.3%

Return on capital employed

-31.6%

Return on sales

-13,243.6%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Relay Therapeutics stock price performed over time

Intraday

0.71%

1 week

9.96%

1 month

-10.94%

1 year

-39.6%

YTD

-35.3%

QTD

18.63%

How have Relay Therapeutics's revenue and profit performed over time

Revenue

$2.02M

Gross profit

$2.02M

Operating income

-$270.8M

Net income

-$267.12M

Gross margin

100%

Net margin

-13,243.6%

Relay Therapeutics's revenue has plunged by 98% YoY and by 19% from the previous quarter

RLAY's gross profit has dropped by 98% year-on-year and by 19% since the previous quarter

Relay Therapeutics's net income has increased by 30% QoQ but it has decreased by 13% YoY

RLAY's operating income is up by 30% since the previous quarter but it is down by 14% year-on-year

What is Relay Therapeutics's growth rate over time

What is Relay Therapeutics stock price valuation

P/E

N/A

P/B

2.77

P/S

1,070.28

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

1,029.01

The EPS has dropped by 144% year-on-year but it has increased by 35% since the previous quarter

The P/B is 28% lower than the last 4 quarters average of 3.8

The equity is up by 26% year-on-year but it has declined by 7% since the previous quarter

Relay Therapeutics's revenue has plunged by 98% YoY and by 19% from the previous quarter

The stock's price to sales (P/S) is 33% more than its last 4 quarters average of 799.9

How efficient is Relay Therapeutics business performance

The ROA is up by 44% YoY and by 34% QoQ

The company's return on equity rose by 41% YoY and by 34% QoQ

The return on invested capital has increased by 38% since the previous quarter and by 37% year-on-year

The return on sales has increased by 14% since the previous quarter

What is RLAY's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for RLAY.

How did Relay Therapeutics financials performed over time

RLAY's quick ratio is down by 28% year-on-year and by 11% since the previous quarter

RLAY's current ratio is down by 27% year-on-year and by 11% since the previous quarter

The debt is 97% less than the equity

The equity is up by 26% year-on-year but it has declined by 7% since the previous quarter

Relay Therapeutics's debt to equity has decreased by 25% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.